⌕
Anbio Biotechnology · NNNN · Nasdaq
Tenet 37 · Weak
Compare
$3.65−5.93%At closeTenet 37 · Weak
$3.65−0.23 (−5.93%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Anbio Biotechnology (NNNN) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

11 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 63% below its peak, net margin 74.1%.
The lines that matter · FY22–FY25
Revenue ($K)▲5.6%
8,646.8
FY22→FY25CAGR −28.4%/yr
Net income ($K)▲169.9%
6,403.5
FY22→FY25CAGR −13.8%/yr
What the income statement says · FY22–FY25
Where every revenue dollar goes · FY25 ($K)8646.8Revenue−1103.7COGS7543.2Gross profit−201.3R&D−1574.1SG&A5767.7Op income635.7Tax & other6403.5Net income

74¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~3%FY22FY25

Over this window: gross 53.4% → 87.2%. Net margin 74.1% is more than double the sector median.

The receipt · income statement · FY22–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemFY25 †FY25FY24FY23FY22YoYCAGR 22→25
Revenue & profitability
Revenue
8,646.88,646.88,185.16,712.023,544.7▲5.6%−28.4%
Cost of revenue
1,103.71,103.72,299.83,351.110,980.8▼52.0%−53.5%
Gross profit
7,543.27,543.25,885.43,360.912,563.8▲28.2%−15.6%
Research & development
201.3201.3454.2134.7200.0▼55.7%+0.2%
Selling, general & admin
1,574.11,574.13,435.81,265.22,168.2▼54.2%−10.1%
Total operating expenses
1,775.41,775.43,890.01,399.92,368.2▼54.4%−9.2%
Operating incomefeeds ROC rank
5,767.75,767.71,995.41,960.910,195.6▲189.1%−17.3%
Other income, net
635.7635.7377.5292.8−184.4——
Pretax income
6,403.56,403.52,372.82,253.710,011.2▲169.9%−13.8%
Income tax
0.00.00.00.00.0——
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
6,403.56,403.52,372.82,253.710,011.2▲169.9%−13.8%
Per share
Diluted EPSbuyback-sensitive
——A—A—A—A——
Diluted shares (mn)
143.89143.89142.29——▲1.1%—
Margins
Gross margin
87.2%87.2%71.9%50.1%53.4%▲15.3pp+33.9pp
Operating margin
66.7%66.7%24.4%29.2%43.3%▲42.3pp+23.4pp
Net margin
74.1%74.1%29.0%33.6%42.5%▲45.1pp+31.5pp
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.A Withheld by our checks.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-04-07 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Anbio Biotechnology's revenue last fiscal year?

Anbio Biotechnology reported revenue of $8,646.8K in fiscal 2025, up 5.6% from fiscal 2024.

What was Anbio Biotechnology's net income?

Anbio Biotechnology reported net income of $6,403.5K in fiscal 2025, a net margin of 74.1%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.